メニュー
Suggests measuring a nadir GH level after an oral glucose load in patients with a postoperative random GH greater than 1 µg/L. Use to further evaluate GH suppression when baseline GH is elevated postoperatively.
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-postop-nadir-gh-ogtt-if-ghgt1コマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
SOC 職業分類に基づく
SKILL.md を表示中
| name | endo-postop-nadir-gh-ogtt-if-ghgt1 |
| description | Suggests measuring a nadir GH level after an oral glucose load in patients with a postoperative random GH greater than 1 µg/L. Use to further evaluate GH suppression when baseline GH is elevated postoperatively. |
Confirm postoperative timing ≥12 weeks after transsphenoidal surgery; obtain serum IGF-1 and random GH levels.
Is random GH >1 µg/L? If NO, consider biochemical remission (especially if IGF-1 normal) and routine follow‑up. If YES, proceed to oral glucose tolerance test (OGTT) for nadir GH measurement.
Perform OGTT (75 g glucose) and measure nadir GH at 0, 30, 60, 90, 120 min; classify as suppressed if nadir GH <1 µg/L, not suppressed if nadir GH ≥1 µg/L.
If nadir GH suppressed (<1 µg/L), continue routine surveillance with IGF-1 and random GH every 6‑12 months. If nadir GH not suppressed (≥1 µg/L), consider persistent disease and discuss repeat surgery, medical therapy, or radiotherapy with multidisciplinary team.
Do not measure GH <12 weeks post‑op due to surgical stress‑induced elevations; ensure fasting state and verify hyperglycemia during OGTT to avoid false‑negative suppression; use assay with adequate sensitivity at low GH levels; do not rely solely on random GH without IGF-1 context; avoid interpreting a single nadir GH without confirming glucose load adequacy.
A patient 4 months postoperatively has random GH 1.8 µg/L and IGF-1 above age‑adjusted norm. OGTT yields nadir GH 0.9 µg/L (<1 µg/L), indicating adequate suppression; patient continues routine monitoring. Another patient with random GH 2.2 µg/L has nadir GH 1.6 µg/L (≥1 µg/L), prompting discussion of repeat surgery or initiation of somatostatin receptor ligand therapy.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
TODO: consider adding scripts/calc.py for the endo-postop-nadir-gh-ogtt-if-ghgt1 calculator